Holen Sie sich die Stockscreener-App
165.96
1.19%
1.955
Schlusskurs vom Vortag:
$164.00
Offen:
$164.05
24-Stunden-Volumen:
8,027
Relative Volume:
0.04
Marktkapitalisierung:
$6.22B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.61M
KGV:
-141.34
EPS:
-1.1742
Netto-Cashflow:
-
1W Leistung:
+4.20%
1M Leistung:
+11.29%
6M Leistung:
+158.67%
1J Leistung:
+196.68%
1-Tages-Spanne:
$163.90
$166.00
1-Wochen-Bereich:
$153.56
$170.25
52-Wochen-Spanne:
$49.00
$170.25
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLTE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
165.81 | 6.15B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.00 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.42 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.45 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.41 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-02 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Eingeleitet | Mizuho | Neutral |
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Belite Bio stock hits all-time high at 169.88 USD By Investing.com - Investing.com India
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target - Investing.com Canada
Belite Bio (NASDAQ:BLTE) Lowered to Sell Rating by Wall Street Zen - Defense World
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target By Investing.com - Investing.com Canada
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
Behavioral Patterns of BLTE and Institutional Flows - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Shares Up 5.5%Should You Buy? - MarketBeat
Belite Bio stock hits all-time high at 163.25 USD - Investing.com
Belite Bio stock hits all-time high at 163.25 USD By Investing.com - Investing.com Australia
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Down 45.2% in December - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Belite Bio (NASDAQ:BLTE) Stock Rating Upgraded by Wall Street Zen - Defense World
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
The $100 ClubWere You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - RTTNews
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Sets New 1-Year HighHere's Why - MarketBeat
Can Belite Bio Inc (Common Stock) (D01) stock attract analyst upgradesMarket Movers & Expert Approved Trade Ideas - Улправда
Belite Bio, IncDepositary Receipt (BLTE) Price Target Increased by 21.98% to 116.02 - MSN
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Sets New 52-Week High – Here’s What Happened - Defense World
Belite Bio Shares Surge After Landmark Phase 3 Success in Stargardt Disease - MSN
Belite Bio (NASDAQ:BLTE) Reaches New 52-Week HighShould You Buy? - MarketBeat
Belite Bio stock hits all-time high at 160.74 USD - Investing.com
Belite Bio stock hits all-time high at 160.74 USD By Investing.com - Investing.com Canada
Price-Driven Insight from (BLTE) for Rule-Based Strategy - news.stocktradersdaily.com
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.9%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Clene (CLNN) and Costco (COST) - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Rating Increased to Outperform at Mizuho - MarketBeat
FY2025 EPS Estimates for Belite Bio Lowered by HC Wainwright - MarketBeat
Belite Bio (NASDAQ:BLTE) Raised to “Outperform” at Mizuho - Defense World
Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering - MSN
Belite Bio (NASDAQ:BLTE) Shares Gap UpWhat's Next? - MarketBeat
Belite Bio stock price target raised to $187 from $132 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio stock price target raised to $187 from $132 at Benchmark - Investing.com Nigeria
Is Belite Bio’s Surge Justified by DCF Upside and Price to Book Signals? - Sahm
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs - The Globe and Mail
Belite Bio Prices $350 Million ADS Offering to Boost Drug Development - TipRanks
Does Belite Bio Inc ADR (BLTE) offer a good opportunity for investors? - Setenews
Mizuho upgrades Belite Bio stock to Outperform on positive trial data By Investing.com - Investing.com South Africa
Mizuho upgrades Belite Bio stock to Outperform on positive trial data - Investing.com Australia
Why Belite Bio’s Stock is Making Waves - TipRanks
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Belite Bio prices public offering of ADSs at $154 each - Investing.com
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):